Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Review uri icon

Overview

abstract

  • Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain parenchyma, spinal cord, eyes, and cerebrospinal fluid without evidence of systemic, non-CNS involvement. PCNSL is uncommon and only a few randomized trials have been completed in the first-line setting. Over the past decades, the prognosis of PCNSL has improved, mainly due to the introduction and widespread use of high-dose methotrexate, which is now the backbone of all first-line treatment polychemotherapy regimens. Despite this progress, durable remission is recorded in only 50% of patients, and therapy can be associated with significant late neurotoxicity. Here, we overview the epidemiology, clinical presentation, staging evaluation, prognosis, and current up-to-date treatment of immunocompetent PCNSL patients.

publication date

  • February 19, 2019

Research

keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Central Nervous System Neoplasms
  • Cranial Irradiation
  • Lymphoma, Large B-Cell, Diffuse

Identity

PubMed Central ID

  • PMC6380418

Scopus Document Identifier

  • 85066963147

Digital Object Identifier (DOI)

  • 10.1093/neuros/nyy096

PubMed ID

  • 30418592

Additional Document Info

volume

  • 21

issue

  • 3